Goal 4: Develop Workforce and Resources

To support the future of investigator-initiated research by sustaining and developing a diverse biomedical workforce with the skills and research resources to pursue emerging opportunities in science.

Goal 4: Develop Workforce and Resources

Which factors are associated with systems performance?

What are the institutional factors, including structure and culture of care, that characterize systems performance? Which of these factors are potentially modifiable and/or scalable?

Submitted by (@rebecca.lehotzky)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea : AHA Staff & Volunteers

Voting

-3 net votes
2 up votes
5 down votes
Active

Goal 4: Develop Workforce and Resources

Specialized centers for cardiac arrest care

Should out-of-hospital cardiac arrest care be regionalized to specialized centers similar to trauma, STEMI, and stroke?

Submitted by (@rebecca.lehotzky)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Compelling Question (CQ)

Name of idea submitter and other team members who worked on this idea : AHA Staff & Volunteers

Voting

-1 net votes
2 up votes
3 down votes
Active

Goal 4: Develop Workforce and Resources

Developing/adapting training programs to address future areas of critical need

What are the best methods to identify future training areas and develop/adapt training and mentorship programs to address future critical needs?

Submitted by (@nhlbiforumadministrator)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Compelling Question (CQ)

Details on the impact of addressing this CQ or CC :

• Increased return on investment

• Cross-fertilization/cross pollinate with other ICs

Feasibility and challenges of addressing this CQ or CC :

High feasibility but may require pilot projects, marketing and dissemination

Name of idea submitter and other team members who worked on this idea : NHLBI Staff

Voting

8 net votes
16 up votes
8 down votes
Active

Goal 4: Develop Workforce and Resources

DEVELOPMENT AND SUPPORT FOR APHERESIS MEDICINE INVESTIGATORS

The apheresis medicine encompasses treatment of numerous diseases many of which are directly related to blood, lung and heart. However, there are very limited opportunities for training young investigators in basic and translational research related to Apheresis Medicine. There is a need to promote Apheresis Medicine as a viable field of research for junior and established investigators. The influx of well-trained junior ...more »

Submitted by (@zbigniew.m.szczepiorkowski)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

Therapeutic apheresis is the process of transiently removing whole blood from the body, separating it into various components (e.g., cells, plasma, proteins, antibodies, antigen-antibody complexes, lipids, etc.), removing those components that contribute to disease, and then returning the remaining blood with possible addition of a blood component to the body.

 

Hundreds of thousands of apheresis procedures are being performed every year in the US. Many of these procedures are life-savings while others are likely to be of limited benefit to patients and healthcare system at large. There is lack of good understanding pertaining to basic mechanisms of apheresis and optimal ways of applying apheresis to the improvement of underlying conditions as well as to the ability of apheresis to enhance other treatment modalities. This in turn is caused by significant shortage of well-educated and trained physician scientists willing to address basic science and translational-clinical questions related to applications of apheresis in clinical practice.

 

Currently there are no specific mechanisms for training such individuals. Utilization of and integration with existing educational/training programs, such as T32 grants, K23/K24/K25 grants, institutional K12 awards and CTSA educational programs would likely result in the cadre of junior investigators who can tackle questions related to basic mechanisms as well as clinical approaches to treating diseases using apheresis strategies.

Feasibility and challenges of addressing this CQ or CC :

Feasibility: Incorporation of apheresis medicine training into currently available resources is likely to be highly feasible. This training can be provided across many medical specialties including hematology, transfusion medicine, cardiology, pulmonology and others. Inclusion of basic scientists involved in research of blood disorders, lung and heart disorders, as well as immunology will expand the outreach. Identification of individuals interested in pursuing research in apheresis medicine might be accomplished on different levels of training starting with medical school, internship, residency and fellowship as well as early years of medical career in a variety of medical specialties.

 

Challenges: The primary challenge is related to perception. Apheresis has an undeserved reputation as an "old" science; one that in recent years has been overtaken at times by newer medical treatments. Yet it still is the only and often life-saving treatment for certain conditions. Apheresis remains the go-to procedure for treating many common and rare maladies alike, such as TTP, and new treatment indications are being added. Although many specialists like hematologists, neurologists, nephrologists see the evidence and benefits of therapeutic apheresis in their everyday work, the progress of Apheresis Medicine as a medical specialty has been generally slow. The other major challenge is lack of funding of basic research and translational research related to Apheresis Medicine.

Name of idea submitter and other team members who worked on this idea : Zbigniew M. Szczepiorkowski, Yanyun Wu on behalf of ASFA

Voting

108 net votes
127 up votes
19 down votes
Active

Goal 4: Develop Workforce and Resources

Pharmacy-Physician Cross-Reference System Required

Why does a cross-reference gap occur when prescriptions are filled through a patient's one and only pharmacy. How can a pharmacist double check a physician's work when the physician prescribes a medication that should NOT be taken if the patient has a diagnosis the pharmacist has no documented evidence to REJECT the prescription and NOT dispense the dangerous drug-interaction, drug vs. medical condition information? Since ...more »

Submitted by (@louisecompanion)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

#1) Tramadol/Ultram was prescribed by hospital discharging physician #1. Prescription paperwork clearly stated that Tramadol should not be administered if you take Cymbalta/Duloxetine. I took Tramadol and Cymbalta together for two (2) years.

 

#2) Seroquel/Quentiamine (generic name ??) was prescribed by physican #2. Prescription paperwork indicates this drug should NOT be taken with the drug SOTALOL/BETAPACE or patients who have Prolonged Q-T Interval or Long QT. I have Long QT and the pharmacist's response to filling the Seroquel prescription, which made me ill, was the Seroquel dose was not too high. That pharmacy also fills my Sotalol.

 

#3) I have been allergic to sulfa drugs. Physician #3 prescribed Polymyxin B Sulfate and Trimethoprim Ophthalmic Solution USP. I was initially prescribed the eye drops on 04-02-2015. Because my left eye continued to bother me, I returned to the same urgent care. I have a Medtronic ICD (implantable cardioverter defibrillator). Medical records clearly indicate that Sulfa drugs affect my cardiovascular system. On 04-14-2015, I returned to the same urgent care for eye pain but, based on my abnormal ECG, cardiovascular was my primary reason for the visit, not my eye. I was told to resume the Polymyxin (full eye drop name above).

 

I didn't find out this data until just recently. If the pharmacist KNEW I had Long QT, perhaps Seroquel would have NEVER been filled, which harmed my conditions.

Feasibility and challenges of addressing this CQ or CC :

Based on the above information, how can pharmacist's double check the doctor's (unfilled) prescriptions without knowledge of the patient's health history? How could a pharmacist fill a drug Seroquel when it shouldn't be combined with Sotalol or those with Long QT? How can this drug-interaction be avoided? How do we fill the gap? I am a serious disabled person who has exhausted herself because she HAS HAD to become a self-appointed, her OWN HEALTH ADVOCATE.

Name of idea submitter and other team members who worked on this idea : Louise Companion

Voting

-10 net votes
0 up votes
10 down votes
Active

Goal 4: Develop Workforce and Resources

Accounting for indirect costs

Strengthen institutional accountability to the investigator for appropriate use of indirect funds

Submitted by (@flogerfo)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

If the PI had some way of affirming institutional accountability for use of indirect funds, it would greatly strengthen PI support and respect. This would result in better space, admin support, support for resubmission,and overall prestige within the institution. The end result would be more effective research and attractiveness of a research career. Clinician scientists would benefit greatly.

Feasibility and challenges of addressing this CQ or CC :

Institutions rarely are interested in accounting to the investigator for use of IDC. Quite possibly due to fear that the investigator would be unreasonable demanding. Some creativity could get around this. A list of Investigators "rights" or "expectations" in terms of institutional support in the effective use of public funds. A committee of PIs to report to NIH on Institutional support. Perhaps with a response for the Institution. The value of this might be judged by the intensity of the pushback from institutions. Nonetheless, hospitals and schools are accountable to JCAH, etc. Having PIs participate in an evaluation by the NIH would in essence be no different.

Name of idea submitter and other team members who worked on this idea : Frank W LoGerfo

Voting

17 net votes
24 up votes
7 down votes
Active

Goal 4: Develop Workforce and Resources

Education in glycobiology is nearly non-existent

Aside from a handful of locations around the country, there are no local opportunities for the vast majority of PhD students to learn about glycobiology. A search on NIH Reporter for T32 grants with "glycobiology” reveals two grants (one NCI for cancer cell biology, one NIGMS for pharmacology). Neither of these grants are focused upon glycobiology. In fact, glycobiology is essentially never integrated into any standard ...more »

Submitted by (@nhlbiforumadministrator)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Feasibility and challenges of addressing this CQ or CC :

I have participated in the American Association of Immunologists Advanced Course in Immunology the past several years. I give a single 90 minute lecture on “glycoimmunology”. While this helps to plant the seed of interest in how glycans impact the immune response and host defense, it is not nearly enough. I suggest the following ideas to begin closing this gap in training:

 

1. Support glycobiology training grants (T32) throughout the country, and not just at the small number of institutions (Emory, UCSD, UGA/CCRC, Johns Hopkins) with existing strength; and 2. Provide an incentive to integrate glycobiology aspects into other T32 proposals targeting the NHLBI to improve integration of the field into the broader context.

 

An important point, however, is that outside of the institutions already mentioned, existing glycobiology training opportunities are rare due to a lack of support. Thus, the NHLBI must be willing to help seed nascent training programs through a targeted funding initiative. As a PI of an immunology-focused T32, it is clear to me that competition for a ‘standard’ T32 in glycobiology would be impossible within the standing CSR T32 panel.

Name of idea submitter and other team members who worked on this idea : Brian Cobb

Voting

2 net votes
2 up votes
0 down votes
Active

Goal 4: Develop Workforce and Resources

Enhancing T4 Implementation Research Expertise

We need to increase our base of T4 implementation research expertise among researchers, reviewers, and investigators.

Submitted by (@nhlbiforumadministrator)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

Increase our base of expertise in a relatively new field. Increase the number of funded grants and projects that include T4 implementation research.

Feasibility and challenges of addressing this CQ or CC :

Additional training for T4 implementation research can be added to the training infrastructure currently in place at the NHLBI/NIH.

Name of idea submitter and other team members who worked on this idea : NHLBI Staff

Voting

-6 net votes
4 up votes
10 down votes
Active

Goal 4: Develop Workforce and Resources

Funding & Review Mechanisms

Funding and review mechanisms are essential resources that can facilitate or hinder innovative research to meet the NHLBI goals. These resources must be refocused to result in identification and funding of the type of innovative research being sought by NHLBI. The opportunities for leveraging available NHLBI funds with other sources should be considered formally as a component of overall budget planning, not just on ...more »

Submitted by (@media0)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

The impact should be more equitable access to funds, as perceived by potential recipients; provision of funds for high-priority topics; and revitalized, refocused review groups that are willing and able to consider recommending high risk, innovative approaches.

Feasibility and challenges of addressing this CQ or CC :

This is a very specific challenge that may require incremental implementation with some experimentation/pretesting and solicitation of ideas from a range of stakeholders identified during this goal-setting exercise. While the Institute may be able to make changes in how funding mechanisms are employed, making changes to review group membership may be more challenging, especially in the current context of recruiting members. Incentives for this service may also need to be reviewed, innovatively, under current budget constraints.

Name of idea submitter and other team members who worked on this idea : Sonja McKinlay. Team Members: Susan Assmann and Paul Stark

Voting

4 net votes
8 up votes
4 down votes
Active

Goal 4: Develop Workforce and Resources

Pipeline of clinician scientists

Maintaining the pipeline of clinician scientists via early and mid-career awards. Promote the development of collaborative teams.

Submitted by (@societyforvascularsurgery)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Name of idea submitter and other team members who worked on this idea : Society for Vascular Surgery

Voting

5 net votes
6 up votes
1 down votes
Active

Goal 4: Develop Workforce and Resources

Ask Dr. Hsia to stop littering the forum to advertise his company

True dialogue is impeded by having to constantly scroll through a repeated posting of the same company advertisement. This is abuse of the forum.

Submitted by (@savebasicresearch)

Is this idea a Compelling Question (CQ) or Critical Challenge (CC)? : Critical Challenge (CC)

Details on the impact of addressing this CQ or CC :

Comment by chsia 05/05/2015

Dear All,

1) Nano Red Blood Cell (NanoRBC) can be used alone or used conjunction with banked blood to improve the potency and safety of transfusable red blood cells.

 

etc.

 

Sincerely,

 

Carleton Hsia, Ph.D.

Chairman&CEO

NanoBlood LLC

Feasibility and challenges of addressing this CQ or CC :

Press Release

FOR RELEASE: Thursday, April 28, 2015

Contact: Natalie Likness, Governor’s Office of Economic Development, 605.773.3301

NanoBlood LLC Relocating to South Dakota

 

SIOUX FALLS, S.D. – NanoBlood LLC, based in Irvine, Calif., announced today that it is relocating to the South Dakota Technology Business Center (SDTBC) in Sioux Falls, S.D., to continue the regulatory and commercial development of its nano red blood cell as a life-saving drug in critical care and transfusion medicine.

 

etc.

 

“I am very grateful and appreciative of Gov. Daugaard’s support of commercial development of nano red blood cell in South Dakota for domestic and global need in critical care and transfusion medicine,” said Carleton Hsia, chairman and CEO of NanoBlood.

Name of idea submitter and other team members who worked on this idea : none

Voting

6 net votes
11 up votes
5 down votes
Active